Gene Therapy for Cancer

  • Kelly K. Hunt
  • Stephan A. Vorburger
  • Stephen G. Swisher

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Vectors

    1. Front Matter
      Pages 1-1
    2. Bingliang Fang, Jack A. Roth
      Pages 3-22
    3. Renata Stripecke, Noriyuki Kasahara
      Pages 39-71
    4. Sricharan Chalikonda, David L. Bartlett
      Pages 73-85
    5. Kenneth Lundstrom
      Pages 109-119
    6. Selvarangan Ponnazhagan
      Pages 141-155
    7. Pui-yan Lee, Leaf Huang
      Pages 157-170
  3. Gene Therapy Approaches

    1. Front Matter
      Pages 171-171
    2. Chao-Zhong Song
      Pages 185-196
    3. Masato Yamamoto, David T. Curiel
      Pages 197-212
    4. Richard H. Pin, Maura Reinblatt, Yuman Fong, William R. Jarnagin
      Pages 213-222
    5. Terry L. Timme, Tetsuo Fujita, Hongyu Wang, Koji Naruishi, Dov Kadmon, Robert J. Amato et al.
      Pages 223-241
    6. Anupama Munshi, Raymond E. Meyn
      Pages 243-256
    7. Steven R. Little, Daniel G. Anderson, Robert S. Langer
      Pages 281-300

About this book

Introduction

The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowing for cellular resistance, and toxicities in clinical trials leading to premature closure of these studies. Different tactics to overcome or circumvent these obstacles have catalyzed the development of a wide range of gene therapy approaches. Thus far, almost two-thirds of gene therapy trials have focused on cancer. This reflects the concept that gene therapy approaches for the treatment of cancer do not necessarily require long-term expression of the gene as is necessary for the treatment of primary genetic defects like hemophilia or juvenile diabetes. Unlike the treatment of genetic defects, where expr- sion of the corrected gene needs to be strong, permanent and, sometimes regulated, tactics to treat tumors can be based on temporary and locally limited effects. In addition, cancer cells have different properties than normal cells and this allows for targeting gene therapy to specific cells, a major advantage over current antitumor therapies, which are also toxic to normal cells and tissues.

Keywords

angiogenesis apoptosis cancer treatment clinical trial gene therapy gene transfer hematopoietic stem cell immune system metastasis ovarian cancer stem cells tumor

Editors and affiliations

  • Kelly K. Hunt
    • 1
  • Stephan A. Vorburger
    • 2
  • Stephen G. Swisher
    • 1
  1. 1.The University of Texas M. D. Anderson Cancer CenterHouston
  2. 2.Inselspital BernUniversity of BernBernSwitzerland

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-59745-222-9
  • Copyright Information Humana Press Inc. 2007
  • Publisher Name Humana Press
  • eBook Packages Medicine
  • Print ISBN 978-1-58829-472-2
  • Online ISBN 978-1-59745-222-9
  • About this book